Novartis Science’s Post

Name: Novartis Science on LinkedIn: Novartis announced an agreement to acquire Mariana Oncology, a…
Uploaded: 2024-05-02T12:42:49.711Z
Channel: Novartis Science
Description: Novartis announced an agreement to acquire Mariana Oncology, a preclinical-stage biotechnology company focused on developing novel radioligand therapies (RLTs) to treat cancers where there is high unmet patient need. https://lnkd.in/gqaSAgAT

Novartis Science

203,498 followers

3mo

Novartis announced an agreement to acquire Mariana Oncology, a preclinical-stage biotechnology company focused on developing novel radioligand therapies (RLTs) to treat cancers where there is high unmet patient need. https://lnkd.in/gqaSAgAT

3 Comments

Kevin Lee

Area Business Leader-Radioligand Therapy

3mo

So proud to be part of this amazing company always focused on improving patient’s lives!

3 Reactions

abdelaziz mahfouz

Project Manager at Mega Business integrated solutions

3mo

good work :)

1 Reaction

Dominic Franck

🔴 Built 3 (#Radiopharma-) labs, Entrepreneur, Value Investor, 🇨🇭Made

3mo

Congrats 🎉😊

1 Reaction

See more comments

To view or add a comment, sign in

More Relevant Posts

evitria AG

2,835 followers
5mo
Report this post
evitria’s journal club - paper of the week no. 11 Antibody Conjugates - Recent Advances and Future Innovations (Jan 2020) from Donmienne Leung et al. Dive into the dynamic world of ADCs with this review! Discover the various formats, conjugations, and payloads revolutionizing oncology treatments and glimpse the future of non-oncology applications. A must-read for enthusiasts in the field! 🧬💊 Want to learn more about how evitria can support your biologics development work? Get in touch today: www.evitria.com/contact #antibodies #research #antibodydrugconjugates
Like Comment
To view or add a comment, sign in
Exigyn

1,294 followers
6mo
Report this post
📉🔍 Gilead's decision to pass on two biotech buyout options signals a strategic shift in its investment approach. Despite initially acquiring almost 50% of Tizona Therapeutics in 2020, Gilead has opted not to pursue a full buyout. Similarly, its earlier option with Pionyr Immunotherapeutics did not materialize into a complete acquisition. This move suggests a reassessment of priorities or a redirection of resources within the company. As Gilead explores new avenues for growth and innovation, the biotech landscape remains dynamic, with opportunities and challenges influencing strategic decisions. #Gilead #BiotechInvestment #StrategicDecisions 📊💼

San Francisco Biotech Networks

5,393 followers
6mo

SFBN Feed: Gilead won’t acquire checkpoint oncology biotech Tizona https://lnkd.in/gTpn7TrW Gilead has now passed on two biotech buyout options that it forged in summer 2020. The large drugmaker will not acquire Tizona Therapeutics, a fellow California biotech working on a new type of checkpoint therapy [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

Gilead won’t acquire checkpoint oncology biotech Tizona

https://sfbn.org
Like Comment
To view or add a comment, sign in
Dr. Timos Papagatsias

BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
4w
Report this post
Thoughts on this? >> Exclusive: Myeloid Therapeutics moves second in vivo cell therapy into trials, targeting liver cancer >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #pharma #productmarketing #pharmaceutical

Exclusive: Myeloid Therapeutics moves second in vivo cell therapy into trials, targeting liver cancer

endpts.com
Like Comment
To view or add a comment, sign in
HLTH Communications

339 followers
3mo Edited
Report this post
Exciting news from Enveric Biosciences, Inc.! Enveric (Nasdaq:ENVB) has inked a $61M licensing deal for patented methods combining cannabinoids with chemotherapy for breast cancer treatment. The exclusive agreement grants the licensee global rights to these groundbreaking methods and related developments. Enveric will receive royalties and milestones, signaling a significant step forward in cancer research. CEO Joseph Tucker expressed optimism about the licensee's innovative approach and the potential impact on cancer patients. With the recent rescheduling of marijuana by the Biden Administration, recognizing its medical benefits, Enveric sees promising opportunities for advancing novel treatments. Check out the latest article in Benzinga! Link in comments! #CancerResearch #Innovation #MedicalBreakthroughs $ENVB Benzinga Cannabis
2 Comments
Like Comment
To view or add a comment, sign in
Allucent

85,646 followers
2w Edited
Report this post
In a recent podcast, Allucent experts Sugato De, MS (VP, Regulatory Strategy, Head of MedTech) and Alex MacDonald, PhD (VP, Model Informed Drug Development) explored the exciting world of antibody drug conjugates (ADCs) and radionuclide drug conjugates (RDCs), discussing the tremendous growth potential of these targeted oncology therapies, the challenges faced by small and mid-sized biotech companies, and strategies for navigating the complex regulatory landscape. This podcast was hosted by BioPharma Dive and can be accessed here: https://lnkd.in/g8uSZp7X. #Allucent #BringNewTherapiesToLife #DrugDiscovery #AntibodyDrugConjugates #Radionuclides #Oncology
Like Comment
To view or add a comment, sign in
LucidQuest

6,221 followers
4w
Report this post
Thoughts on this? >> Exclusive: Myeloid Therapeutics moves second in vivo cell therapy into trials, targeting liver cancer >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #biotech #healthcare #pharma

Exclusive: Myeloid Therapeutics moves second in vivo cell therapy into trials, targeting liver cancer

endpts.com
Like Comment
To view or add a comment, sign in
François Audhuy

Global Medical Affairs Oncology – Strategy & Pipeline
4mo
Report this post
The antibody–drug conjugate (ADC) landscape is rapidly evolving and has become a significant therapeutic modality in oncology. The publication offers a nice overview of the ADC landscape. https://lnkd.in/eSGNKSEB

The antibody–drug conjugate landscape

nature.com
Like Comment
To view or add a comment, sign in
Abhivandan Nagia

Director at ABNewswire
8mo
Report this post
Nonmelanoma Skin Cancer Market: Latest Study by DelveInsight Forecasts Remarkable Growth During the Forecast Period (2023-32) | Sirnaomics, AiViva BioPharma, Exicure, Sanofi, Genentech #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech

Nonmelanoma Skin Cancer Market: Latest Study by DelveInsight Forecasts Remarkable Growth During the Forecast Period (2023-32) | Sirnaomics, AiViva BioPharma, Exicure, Sanofi, Genentech | ABNewswire

https://www.abnewswire.com/pressreleases
Like Comment
To view or add a comment, sign in
World Research Reports

16,174 followers
2mo
Report this post
Targeted Therapeutics Market Size, Share & Trends Analysis Report By Product Type (Monoclonal Antibodies, Small Molecules), By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Sclerosis, Renal Cancer, Wet Age-related Macular Degeneration), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2028. 𝐈𝐧𝐭𝐞𝐥𝐥𝐞𝐜𝐭𝐮𝐚𝐥 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐘𝐨𝐮 𝐜𝐚𝐧 𝐜𝐡𝐞𝐜𝐤 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭:⬇ https://lnkd.in/dbqxJURB 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐖𝐨𝐫𝐤𝐢𝐧𝐠 𝐈𝐧 𝐓𝐡𝐞 𝐌𝐚𝐫𝐤𝐞𝐭:⬇ Pfizer AstraZeneca Amgen Arcus Biosciences Aurinia Pharmaceuticals Inc. Gilead Sciences Roche Genentech Agenus Celdara Medical Nektar Therapeutics
Like Comment
To view or add a comment, sign in
Walter Torres

Experienced Clinical Research professional with a well-rounded background in Oncology and other therapeutic areas
3mo
Report this post
Great improvement in the delivery of innovative CAR-T cell therapies to cancer patients

BioSpace

116,102 followers
3mo

Astellas Pharma and Poseida Therapeutics, Inc. have entered into a second CAR-T contract to develop novel and flexible allogeneic cell therapies in oncology. #news #biospace https://hubs.li/Q02vRYZX0

Astellas Inks Second CAR-T Agreement with Poseida to Develop ‘Convertible’ Cancer Therapies | BioSpace
Like Comment
To view or add a comment, sign in

203,498 followers

View Profile Follow

Novartis Science’s Post

More Relevant Posts

Explore topics